Overview

Oral Abuse Potential Study of Nalbuphine

Status:
Completed
Trial end date:
2020-06-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients). The amount of nalbuphine levels in the blood will also be measured and the safety of the study drugs will be evaluated. This study has 2 parts: Part A and Part B.
Phase:
Phase 1
Details
Lead Sponsor:
Trevi Therapeutics
Collaborator:
Syneos Health
Treatments:
Hydromorphone
Nalbuphine
Pharmaceutical Solutions